CompletedNCT05383456
The Visceral Adiposity Measurement and Observation Study
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Theratechnologies
- Principal Investigator
- Jordan Lake, MDThe University of Texas Health Science Center, Houston
- Intervention
- Diagnostic Test(diagnostic_test)
- Enrollment
- 196 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2023
Study locations (7)
- Ruane Clinical Research, Los Angeles, California, United States
- AIDS Healthcare Foundation, Fort Lauderdale, Florida, United States
- AIDS Healthcare Foundation, Miami Beach, Florida, United States
- Bliss Health, Orlando, Florida, United States
- AIDS Healthcare Foundation, New York, New York, United States
- Fight Community Health Centers, Philadelphia, Pennsylvania, United States
- Prism Health North Texas, Dallas, Texas, United States
Collaborators
Dacima Consulting · Medpace, Inc. · Vanderbilt University Medical Center · Echosens
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05383456 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07091734Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024University of Michigan
- RECRUITINGNCT02325674MEASuRE: Metreleptin Effectiveness And Safety RegistryAmryt Pharma
See all trials for Lipodystrophy due to peptidic growth factors deficiency →